The venue for this event is The Royal College of Pathologists
2 Carlton House Terrace is the home of the Royal College of Pathologists, a professional membership organisation, concerned with all matters relating to the science and practice of pathology.
Carlton House Terrace was constructed largely between 1826 and 1829 and it remains the property of the Queen. Its balconies overlook the Mall in central London where Buckingham palace stands.
This is a Euroscicon Small Conference, an outline of the day can be found at
This 4th Annual event will review the drawback and advantages of hIPSCs for diverse type of clinical applications.
This event has CPD accreditation
This event is part of the 2013 Euroscicon Stem Cell Trilogy. To find out more see www.stemcells2013.com
Dr Lyn Healy, NIBSCC, South Mimms, UK
9:00 – 9:45 Registration
9:45 – 10:00 Introduction by the Chairs: Dr Lyn Healy, NIBSCC, South Mimms, UK
10:00 – 10:40 Deriving Metabolically Active Hepatocytes from Pluripotent Stem Cells
Dr David Hay, MRC Centre for Regenerative Medicine, University of Edinburgh, Scotland
Faithfully recapitulating human physiology “in a dish” from a renewable source remains a holy grail for medicine and pharma. Many procedures have been described that, to a limited extent, exhibit human tissue specific function in vitro. In particular, incomplete cellular differentiation and/or the loss of cell phenotype post-differentiation play a major part in this void. We have developed an interdisciplinary approach to address this problem, employing skill sets in cell biology, materials chemistry and pharmacology. Pluripotent stem cells were differentiated to hepatocytes before being re-plated onto a synthetic surface. Our approach yielded metabolically active hepatocyte populations that displayed stable function for over two weeks in vitro. Although metabolic activity was an important indication of cell utility, the accurate prediction of cellular toxicity in response to specific pharmacological compounds represented our goal. Therefore, detailed analysis of hepatocellular toxicity was performed in response to well defined compounds and compared to primary human hepatocytes. Importantly, stem cell derived hepatocytes displayed equivalence to primary human material. Moreover, we demonstrated that our approach was capable of modelling metabolic differences frequently observed in the population.
10:40 – 11:20 Biophysical considerations of differentiation and reprogramming in embryonic stem cells
Dr Kevin Chalut, University of Cambridge, United Kingdom
11:20 – 11:50 Speakers’ photo then mid-morning break and trade show
Please try to visit all the exhibition stands during your day at this event. Not only do our sponsors enable Euroscicon to keep the registration fees competitive, but they are also here specifically to talk to you
11:50 – 12:30 Surround yourself with support – showcasing services and products from Life Technologies™
Dr Roland Leathers, Life Technologies, UK
This session will showcase the services and products that are available to you to support your stem cell research. We will also include a recent example where we have worked directly with the Parkinson’s Institute to generate iPSC from patients. In collaboration we utilised several technologies including semi-conductor sequencing to characterise these patient cell lines.
12:30 – 13:10 Stemming Visual Loss Using Pluripotent Stem Cells
Professor Pete Coffey, Head of Ocular Biology & Therapeutics, UCL Institute of Ophthalmology, London, UK
The London Project to Cure Blindness was launched at the UCL Institute of Ophthalmology in June 2007, and aims to make the most of human embryonic stem cells to prevent blindness and restore sight in patients with Age-related Macular Degeneration (AMD) by 2013. Our goal is to replace cells essential for “seeing” lost by disease at the back of the eye. We aim to repair and regenerate the aged diseased eye using human embryonic stem cells which have been transformed into the cells affected in AMD: the support cells for the photoreceptors (retinal pigment epithelium) and the photoreceptors. The cells will be surgically implanted into a clinical population of AMD patients.
13:10 – 14:10 Lunch and trade show
14:10– 14:50 Using iPS cells to model embryo development
Dr Ramiro Alberio, University of Nottingham, UK
The development of new cellular reprogramming technologies has enabled the reversal of differentiation of somatic cells into undifferentiated cells. Modulation of the signalling pathways as well as selection of specific exogenous factors for iPS production can lead to the generation of cells with different pluripotent characteristics that can be used to recapitulate normal embryo development in vitro. Our laboratory is using the new understanding on metastable states of pluripotency to model the developmental transitions during embryo development and exploit this features to generate animal cells amenable able to contribute efficiently to germline chimeras.
Our studies are focused in the differentiation of pluripotent cells into germ cell precursors in different species. Elucidating the program of germ cell differentiation is of critical importance for developing safe technologies that will enable the generation of artificial gametes.
14:50 – 16:00 Question and Answer Session
Delegates will be asked to submit questions to a panel of experts. Questions can be submitted before the event or on the day
16: 00 - 16:30 Chairman’s summing up
About the Speakers
Dr David Hay is a Principal Investigator at the University of Edinburgh’s MRC Centre for Regenerative Medicine. David has worked in the field of stem cell biology and differentiation over the last decade. David’s work has highlighted the important role that cell physiology and chemical biology plays in the generation of predictive and drug inducible human hepatocytes from pluripotent stem cells. The impact of this work has led to a number of publications and regular appearances at high profile international conferences. Most recently David and his colleagues spun out a company from the University of Edinburgh, FibromEd, whose focus is to reduce the cost of human drug attrition.
Roland Leathers finished his PhD in cell and molecular biology at the University of Sheffield University, UK in 1989. Following a post-doc in Sheffield, he moved to the Ecole Polytechnique Federale de Lausanne (EPFL) in Switzerland to lead an industrial research collaboration with Hoffmann La Roche. Roland joined Life Technologies in 1993 and has since occupied various positions within the organization. He is currently Strategic Alliances Manager for the Stem Cell and Drug Discovery business unit with geographical responsibility across Europe, India and Australasia.
Ramiro Alberio is a Lecturer in Developmental Epigenetics at the University of Nottingham, UK. Research in his laboratory focuses in developing cellular reprogramming technologies, and in the study of pluripotency in different mammalian species. The laboratory uses stem cells from mouse, human and pig to determine the common pathways used by pluripotent cells. This knowledge is used to design protocols for iPS generation, and to study their differentiation potential in vivo and in vitro. He is co-founder of EvoCell Ltd., a University spin-off company that commercializes stem cell technologies developed in his laboratory.
Keywords: iPSC, hepatocyte, liver, CYP p450, translation, supply chain, delivery, GMP, manufacturing,drug, pluripotent stem cell, hepatocyte, pancreas, liver; beta-cell, Stable Karyoytpe, High-throughput efficiency, Embryonic Stem cells, Induced pluripotency, Nanog, neural stem cell, glioblastoma, DNA methylation, reprogramming, iPS cells, reprogramming, Pluripotentcy, STEMCCA, ESGRO 2i, Pluripotency; reprogramming; chromatin signatures; DNA replication timing; histone acetyltransferase p30, hESC, Drug Metabolism, Hepatocyte, Liver, reprogramming, characterisation, Parkinsons, culture
Event Web Site: www.regonline.co.uk/IPS2013
Phone: 07507 799380
For accommodation and travel please contact email@example.com
For enquiries regarding payment email: firstname.lastname@example.org
You can pay by - Credit card, Cheque, Purchase Order or Bank transfer.
Payment must be received prior to the meeting
You can pay during your online registration using your credit card. The information taken will be by secure server and we use Worldpay and PayPal for our credit card transactions. We always prefer debit cards for transactions, but can also take credit cards and American Express. Using this mode of payment you can guarantee that your fee has reached us prior to the conference and you will be listed as registered
Cheques should be made payable to Euroscicon and mailed (together with a print out of the invoice which will be available at the end of the registration process). After registration you will be emailed details of where to send your cheque.
Please input your Purchase Order number in the box provided once you have selected your mode of payment and an invoice will be sent to you accordingly
Clients organizing bank transfers from non-UK banks will need to pay an additional administration fee of £15.00. Please ensure that you add this fee onto your payment to ensure successful registration. After registration you will be emailed details of where transfer your money.
An event from European Scientific Conferences - Euroscicon "Specialising in communicating cutting edge technology & methodology in the Life Sciences"
EuroSciCon Ltd. Registered in England and Wales,
Company number: 4326921, Registered Office: 47 Falkland Road, High Barnet, EN5